Zobrazeno 1 - 10 of 121 pro vyhledávání: '"John N Allan"'
2
Akademický článek
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
Autor: Francesca Arruga, Marta Rubin, Despoina Papazoglou, Andrea Iannello, Nikolaos Ioannou, Riccardo Moia, Davide Rossi, Gianluca Gaidano, Marta Coscia, Luca Laurenti, Giovanni D’Arena, John N. Allan, Richard R. Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio
Publikováno v: Haematologica, Vol 108, Iss 8 (2023)
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory checkpoint receptor that negatively regulates Tcell responses. CD226 competes with TIGIT for binding to the CD155 ligand, delivering a positive signal to the T cell. Here we stud
Externí odkaz: https://doaj.org/article/1d0bf1e229914fc2a812f673e329ebdb
Zobrazit plný text záznamu
3
Akademický článek
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
Autor: Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Allison Winter, Nicole Lamanna, Constantine S. Tam, Ryan Jacobs, Frederick Lansigan, Paul M. Barr, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Alison R. Sehgal, Stephen J. Schuster, Nirav N. Shah, Chaitra S. Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, the GIMEMA, European Research Initiative (ERIC) on CLL, US study group
Publikováno v: Cancer Medicine, Vol 9, Iss 22, Pp 8468-8479 (2020)
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patie
Externí odkaz: https://doaj.org/article/51d4f3af2edb4e18930e0b7ba14d8eff
Zobrazit plný text záznamu
5
Akademický článek
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL
Autor: Alessandro Pastore, Federico Gaiti, Sydney X. Lu, Ryan M. Brand, Scott Kulm, Ronan Chaligne, Hongcang Gu, Kevin Y. Huang, Elena K. Stamenova, Wendy Béguelin, Yanwen Jiang, Rafael C. Schulman, Kyu-Tae Kim, Alicia Alonso, John N. Allan, Richard R. Furman, Andreas Gnirke, Catherine J. Wu, Ari M. Melnick, Alexander Meissner, Bradley E. Bernstein, Omar Abdel-Wahab, Dan A. Landau
Publikováno v: Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
In chronic lymphocytic leukemia (CLL), evolution is driven by transcriptional and epigenetic heterogeneity. Here, the authors integrate epigenomic analyses to show how intra-tumoral epigenetic diversity results in divergent chromatin states in CLL ce
Externí odkaz: https://doaj.org/article/84f8fc2c23c040aca441459292bfd167
Zobrazit plný text záznamu
6
Akademický článek
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Autor: Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v: Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz: https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6
Zobrazit plný text záznamu
9
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
Autor: Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O'Brien, Andrew P. Grigg, Patricia Walker, Cathy Zhou, Joi Ninomoto, Gabriel Krigsfeld, Constantine S. Tam
Publikováno v: Clinical Cancer Research. 28:4385-4391
Purpose: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6600a849f5c1c6f9585e59d817a67e7e
https://doi.org/10.1158/1078-0432.ccr-22-0504
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje